Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000069.xml
Download PDF
Semin Liver Dis 2003; 23(1): 059-068
DOI: 10.1055/s-2003-37585
DOI: 10.1055/s-2003-37585
Hepatitis B in Children
Further Information
Publication History
Publication Date:
03 March 2003 (online)
ABSTRACT
Childhood hepatitis B virus (HBV) infection presents both medical and public health challenges. Infants who acquire HBV perinatally have up to 90% risk of developing chronic HBV infection. Many HBV-infected children have normal alanine aminotransferase values and minimal chronic hepatitis. Children with chronic HBV infection are usually asymptomatic but may develop chronic liver disease or hepatocellular carcinoma. Both interferon-alfa and lamivudine are available for the treatment of chronic hepatitis B in children, but the optimal treatment of children with chronic HBV infection is evolving as the indications, timing, efficacy, and side effects of the treatments are better understood. Universal infant vaccination has been shown to decrease the frequency of HBV infection and its sequelae. This article addresses aspects of HBV infection that are either unique to or different in children.
KEYWORDS
Hepatitis B - infants - children - perinatal - vaccination - treatment
REFERENCES
- 1 Anonymous. Achievements in Public Health: hepatitis B vaccination-United States, 1982-2002. MMWR Morb Mortal Wkly Rep . 2002; 51 549-552
- 2 McQuillan G M, Coleman P J, Kruszon-Moran D. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health . 1999; 89 14-18
- 3 Goldstein S T, Alter M J, Williams I T. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998; implications for vaccination programs. J Infect Dis . 2002; 185 713-719
- 4 Hsu H Y, Chang M H, Chen D S, Lee C Y, Sung J L. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984; a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol . 1986; 18 301-307
- 5 Ni Y H, Chang M H, Huang L M. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med . 2001; 135 796-800
- 6 Barr D, Hershow R, Furner S, Handler A, Levy P. Assessing prenatal hepatitis B screening in Illinois with an inexpensive study design adaptable to other jurisdictions. Am J Public Health . 1999; 89 19-24
- 7 Shiraki K. Toward control of hepatitis B in the Asia-Pacific region. J Gastroenterol Hepatol . 2000; 15 E11-E15
- 8 Lee S-D, Tsai Y-T, Wu T-C. Role of caesarean section in prevention of mother-infant transmission of hepatitis B virus. Lancet . 1988; 2 833-834
- 9 Beasley R P, Stevens C E, Shiao I S, Meng H C. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B. Lancet . 1975; 2 740-741
- 10 Pickering L. 2000 Red Book: Report of the Committee of Infectious Disease. Elk Grove Village, IL: American Academy of Pediatrics 2000: 98-101
MissingFormLabel
- 11 Lok A S. Hepatitis B infection: pathogenesis and management. J Hepatol . 2000; 32 89-97
- 12 Chu C M, Liaw Y F. Natural history of chronic hepatitis B virus infection: an immunopathological study. J Gastroenterol Hepatol . 1997; 12 S218-S222
- 13 Rehermann B, Lau D, Hoofnagle J H, Chisari F V. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest . 1996; 97 1655-1665
- 14 Shiraki K, Yoshihara N, Sakurai M, Eto T, Kawana T. Acute hepatitis B in infants born to carrier mother with the antibody to hepatitis B e antigen. J Pediatr . 1980; 97 768-770
- 15 Kao J H, Hsu H M, Shau W Y, Chang M H, Chen D S. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr . 2001; 139 349-352
- 16 Cacciola I, Cerenzia G, Pollicino T. Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection. J Hepatol . 2002; 36 426-432
- 17 Kleinknecht C, Levy M, Peix A. Membranous glomerulonephritis and hepatitis B surface antigen in children. J Pediatr . 1979; 95 946-952
- 18 Southwest Pediatric Nephrology Study Group. Hepatitis B surface antigenemia in North American children with membranous glomerulonephropathy. J Pediatr . 1985; 106 571-578
- 19 Lok A SF, Lai C L. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology . 1988; 8 1130-1133
- 20 Lok A SF, Lai C L, Su P C. Treatment of chronic hepatitis B with interferon: experience in Asian patients. Semin Liver Dis . 1989; 9 249-253
- 21 Hsu H-Y, Chang M-H, Lee C-Y. Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection. Hepatology . 1992; 15 382-386
- 22 Bortolotti F, Cadrobbi P, Crivellaro C. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology . 1990; 99 805-810
- 23 Chen P J, Chen D S. Hepatitis B virus infection and hepatocellular carcinoma: molecular genetics and clinical perspectives. Semin Liver Dis . 1999; 19 253-262
- 24 McMahon B J, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med . 2001; 135 759-768
- 25 Tanaka T, Miyamoto H, Hino O. Primary hepatocellular carcinoma with hepatitis B virus-DNA-integration in a 4-year-old boy. Hum Pathol . 1986; 17 202-204
- 26 Cheah P L, Looi L M, Lin H P, Yap S F. Childhood primary hepatocellular carcinoma and hepatitis B virus infection. Cancer . 1990; 65 174-176
- 27 Giacchino R, Navone C, Facco F. HBV-DNA-related hepatocellular carcinoma occurring in childhood. Report of three cases. Dig Dis Sci . 1991; 36 1143-1146
- 28 Pontisso P, Basso G, Perilongo G. Does hepatitis B virus play a role in primary liver cancer in children of Western countries?. Cancer Detect Prev . 1991; 15 363-368
- 29 Hsu H C, Wu M Z, Chang M H, Su I J, Chen D S. Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. Report of 51 cases strongly associated with rapid development of liver cirrhosis. J Hepatol . 1987; 5 260-267
- 30 Chang M H, Chen C J, Lai M S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med . 1997; 336 1906-1907
- 31 Ruíz-Moreno M, Rua M J, Molina J. Prospective, randomized trial of interferon-alpha in children with chronic hepatitis B. Hepatology . 1991; 13 1035-1039
- 32 Barbera C, Bortoletti F, Crivellaro C. Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. Hepatology . 1994; 20 287-290
- 33 Narkewicz M R, Smith D, Silverman A. Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment. J Pediatr . 1995; 127 815-818
- 34 Vajro P, Tedesco M, Fontanella A. Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection. Pediatr Infect Dis J . 1996; 15 223-231
- 35 Sokal E M, Conjeevaram H S, Roberts E A. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology . 1998; 114 988-995
- 36 Lai C L, Lok A S, Lin H J. Placebo-controlled trial of recombinant alpha2-interferon in Chinese HBsAg-carrier children. Lancet . 1987; 2 877-880
- 37 Lai C L, Lin H J, Lau J N. Effect of recombinant alpha2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med . 1991; 78 155-163
- 38 Sokal E M. Viral hepatitis throughout infancy to adulthood. Acta Gastroenterol Belg . 1998; 61 170-174
- 39 Giacchino R, Main J, Timitilli A. Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B. Liver . 1995; 15 143-148
- 40 Gurakan F, Kocak N, Ozen H, Yuce A. Comparison of standard and high dosage recombinant interferon alpha 2b for treatment of children with chronic hepatitis B infection. Pediatr Infect Dis J . 2000; 19 52-56
- 41 Torre D, Tambini R. Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis. Clin Infect Dis . 1996; 23 131-137
- 42 Korenman J, Baker B, Waggoner J. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med . 1991; 114 629-634
- 43 Lin S M, Sheen I S, Chien R N, Chu C M, Liaw Y F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology . 1999; 29 971-975
- 44 Kocak N, Gurakan F, Saltik I N, Ozen H, Yuce A. Long term prognosis of interferon nonresponder children with hepatitis B. Am J Gastroenterol . 2000; 95 1841
- 45 Ruíz-Moreno M, Fernández P, Leal A. Pilot interferon-β trial in children with chronic hepatitis B who had previously not responded to interferon-alfa therapy. Pediatrics . 1997; 99 222-225
- 46 Ballauff A, Schneider T, Gerner P. Safety and efficacy of interferon retreatment in children with chronic hepatitis B. Eur J Pediatr . 1998; 157 382-385
- 47 Iorio R, Pensati P, Botta S. Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J . 1997; 16 984-990
- 48 Gottrand F, Michaud L, Guimber D. Influence of recombinant interferon alpha on nutritional status and growth pattern in children with chronic viral hepatitis. Eur J Pediatr . 1996; 155 1031-1034
- 49 Comanor L, Minor J, Conjeevaram H S. Impact of chronic hepatitis B and interferon-alfa therapy on growth of children. J Viral Hepat . 2001; 8 139-147
- 50 Lai C-L, Chien R-N, Leung N WY. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med . 1998; 339 61-68
- 51 Dienstag J L, Schiff E R, Wright T L. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med . 1999; 341 1256-1263
- 52 Liaw Y-F, Leung N WY, Chang T-T. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology . 2000; 119 172-180
- 53 Leung N W, Lai C L, Chang T T. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology . 2001; 33 1527-1532
- 54 Jonas M M, Kelley D A, Mizerski J. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med . 2002; 346 1706-1713
- 55 Dikici B, Bosnak M, Kara I H. Lamivudine and interferon-alpha combination treatment of childhood patients with chronic hepatitis B infection. Pediatr Infect Dis J . 2001; 20 988-992
- 56 Smith N, Yusuf H, Averhoff F. Surveillance and prevention of hepatitis B virus transmission. Am J Public Health . 1999; 89 11-13
- 57 Yuen M F, Lim W L, Cheng C C, Lam S K, Lai C L. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology . 1999; 29 924-927
- 58 Szmuness W, Stevens C E, Harley E J. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med . 1980; 303 833-841
- 59 Anonymous. Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep . 1996; 45 1-35
- 60 Ascherio A, Zhang S M, Hernan M A. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med . 2001; 344 327-332
- 61 Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med . 2001; 344 319-326
- 62 Giacchino R, Main J, Timitilli A. Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B. Liver . 1995; 15 143-148